Dynavax Technologies Corporation (DVAX) Research

Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's lead product is HEPLISAV-B, a vaccine approved for adults 18 years and older in the U.S. and Europe, which offers protection against all identified subtypes of the hepatitis B virus. Additionally, Dynavax produces and distributes CpG 1018, the specific adjuvant ingredient used in HEPLISAV-B. Dynavax maintains several strategic alliances, including a collaboration agreement with Valneva Scotland Limited, an agreement with Serum Institute of India Pvt. Ltd., and a sublicense agreement with Merck, Sharp & Dohme Corp. The company, incorporated in 1996, was originally named Double Helix Corporation before adopting the name Dynavax Technologies Corporation in September of that year. Its corporate headquarters are situated in Emeryville, California.

Market snapshot

Symbol
DVAX
Price
$15.50
Day change
0.00%
Market cap
$1.8B
P/E ratio
-41.89x
52-week range
9.2-15.73
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Analyst price target
$27.00

Peer companies

  • Amphastar Pharmaceuticals, Inc. (AMPH)
  • Beta Bionics, Inc. (BBNX)
  • Collegium Pharmaceutical, Inc. (COLL)
  • Enliven Therapeutics, Inc. (ELVN)
  • Evotec SE (EVO)
  • Harrow Health, Inc. (HROW)
  • Immatics N.V. (IMTX)
  • Pacira BioSciences, Inc. (PCRX)

Recent insider activity

  • Deep Track Biotechnology Master Fund, Ltd. — U-Tender (15726349 shares) on 2026-02-10
  • Spencer Ryan — A-Award (165000 shares) on 2026-02-10
  • Spencer Ryan — A-Award (136000 shares) on 2026-02-10
  • Spencer Ryan — D-Return (90667 shares) on 2026-02-10
  • Spencer Ryan — U-Tender (379620 shares) on 2026-02-10

Open Dynavax Technologies Corporation (DVAX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.